Can a chaotic FDA still deliver on faster drug development?
Summary:
Despite leadership turnover and organizational instability at the FDA, regulators and industry remain committed to accelerating drug development, though experts caution that achieving faster clinical trials will require clear implementation strategies, sufficient staffing, and coordinated support across the broader U.S. healthcare ecosystem
Tango plans Phase 3 pancreatic cancer study after combo success
Summary:
Tango Therapeutics reported a remarkable 92% response rate in previously treated pancreatic cancer patients receiving vopimetostat plus daraxonrasib, providing early evidence that targeted combination therapies could reshape treatment options for genetically defined subsets of one of the deadliest cancers.
What’s behind China’s historically high counts of corresponding authors?
Summary:
A large-scale scientometric analysis found that researchers in China were significantly more likely to designate multiple corresponding authors than their global peers between 2016 and 2020, highlighting how research evaluation systems can shape authorship practices and how recent policy reforms may strengthen transparency and research integrity
03 key takeaways from ADA
Summary:
Tandem Diabetes Care, Insulet and Dexcom all presented data over the weekend at the American Diabetes Association’s Scientific Sessions.
Bots are scraping open data — how should researchers respond?
Summary:
The snowballing ability of artificial intelligence to trawl open data sets has some scientists worried about losing control of their information.
